Hippocratic AI Valuation, Funding & Investors

Hippocratic AI is valued at $3.5B as of November 2025.

Last Hippocratic AI valuation

$3.5B

Series C · Nov 2025

Last Hippocratic AI funding round

$126M

Series C · Nov 2025

Cumulative funding Hippocratic AI raised

$402M

across 6 funding rounds

Key investors in Hippocratic AI

Hippocratic AI Overview

About Hippocratic AI

Hippocratic AI is a San Francisco-headquartered developer of large language models optimized for non-diagnostic healthcare interactions. Its platform deploys AI agents for tasks like preoperative education, discharge instructions, and chronic disease follow-ups via phone or text. Built on a multi-agent architecture with clinician oversight, the system includes an agent marketplace for specialties such as cardiology and oncology. Health systems integrate agents into workflows for patient outreach and triage support.


Founded

2023

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$3.5B (Nov 2025)

Hippocratic AI Valuation

Hippocratic AI is currently valued at $3.5B, based on its Series C in November 2025.

The $126M round was led by Avenir, with participation from General Catalyst, Kleiner Perkins, John Doerr, Cincinnati Children’s, Premji Invest and 5 other investors.

Hippocratic AI's valuation has grown 7.0x from $500M at its Series A in March 2024 to $3.5B in November 2025, across 4 priced rounds.

Hippocratic AI valuation by funding round

Hippocratic AI valuation by funding round
DateStageValuation
Nov 2025Series C$3.5B
Jan 2025Series B$1.6B
Sep 2024Series A$500M
Mar 2024Series A$500M

Hippocratic AI Funding History

Hippocratic AI has raised a total of $402M across 6 funding rounds.

Hippocratic AI's first fundraising round was a $50M seed round in May 2023. The most recent completed round was a $126M Series C in November 2025.

Hippocratic AI funding rounds

Hippocratic AI funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Nov 2025Series CAvenir (lead); General Catalyst; Kleiner Perkins; John Doerr; Cincinnati Children’s; Premji Invest; Andreessen Horowitz; CapitalG; Universal Health Services; Rick Klausner; WellSpan Health$126M$3.5BHippocratic AI, a Palo Alto-based healthcare AI startup founded in 2023 with General Catalyst and Flagship Pioneering, develops safety-focused generative AI agents for non-diagnostic, patient-facing tasks such as appointment scheduling, intake histories, social determinant screenings, chronic disease management, and post-discharge follow-ups. The agents leverage the proprietary Polaris Safety Constellation Architecture, which employs multiple large language models to cross-verify outputs for clinical accuracy and safety, ensuring no diagnostic or prescriptive functions. In 15 months since commercialization, the company has partnered with over 50 large health systems, payors, and pharmaceutical clients across six countries, including Cleveland Clinic, Northwestern Medicine, Moffitt Cancer Center, and Guy’s & St Thomas’ NHS Trust, developing more than 1,000 clinical use cases and completing over 115 million patient interactions without safety issues. On November 3, 2025, Hippocratic AI closed a $126 million Series C funding round led by Avenir Growth, achieving a $3.5 billion post-money valuation and bringing total funding to $404 million. This followed a $141 million raise earlier in 2025 at a $1.64 billion valuation and a $235 million tranche in September co-led by Braidwell and Collective Global. Participants included CapitalG, Andreessen Horowitz, General Catalyst, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children’s Hospital Medical Center, WellSpan Health, John Doerr, Rick Klausner, and others such as NVentures, Analog Devices, and Catalio Capital Management. Investors praised the company's rapid growth, safety focus, and leadership in agentic healthcare AI amid industry challenges like labor shortages and patient access constraints. Proceeds will support product development, international expansion, selective M&A, and enhancements to the safety architecture to scale deployments globally. CEO Munjal Shah emphasized adhering to 'do no harm' and 'patients first' principles to broaden access and dignity in care. The round underscores surging investor confidence in safe, scalable AI solutions for healthcare, positioning Hippocratic AI as one of the sector's most valuable startups despite broader market caution toward AI investments.
Jan 2025Series BKleiner Perkins (lead); NVIDIA; General Catalyst; SV Angel; Premji Invest; Andreessen Horowitz; Universal Health Services; WellSpan Health$141M$1.6BHippocratic AI develops safety-focused large language models (LLMs) for patient-facing, non-diagnostic healthcare tasks such as medication onboarding, reconciliation, policy questions, and EHR assistance. The company's Polaris constellation LLM architecture emphasizes safety through collaboration with health systems like Universal Health Services, WellSpan Health, and others, achieving milestones like Polaris 2.0 with 3.7 trillion parameters. In January 2025, it completed a $141 million Series B round led by Kleiner Perkins, with participation from Andreessen Horowitz, General Catalyst, NVIDIA, Premji Invest, SV Angel, Universal Health Services, and WellSpan Health, valuing the company at $1.64 billion post-money and achieving unicorn status. The funding, announced nine months after a $53 million Series A (plus $17 million extension totaling $137 million previously), will expand into pharma and payor verticals, new markets including EMEA, Southeast Asia, and Latam, and support the launch of a Healthcare AI Agent App Store. This app store enables licensed clinicians to co-design AI agents for specific use cases, earning revenue from customer adoption, with each agent safety-tested in under 30 minutes. Kleiner Perkins partner Mamoon Hamid highlighted the company's commercial traction and the massive addressable market for AI in addressing healthcare staffing shortages, estimated at 10 times the healthcare software market. Hippocratic AI's approach differentiates by targeting patient-facing activities with rigorous safety standards, refusing to launch until matching human nurse safety levels. The firm has partnerships for clinician training and holds U.S. patents on its LLM innovations. Subsequent developments include a November 2025 Series C raising $126 million at $3.5 billion valuation led by Avenir Growth, with many overlapping investors, to fund global expansion, M&A, and over 1,000 clinical use cases handling 115 million patient interactions across 50+ partners in six countries.
Sep 2024Series ANVentures (lead); 7wire Ventures; Greycroft; Michal Valko$17M$500MHippocratic AI develops safety-focused large language models and generative AI agents for non-diagnostic healthcare applications, including patient-facing conversational AI. The company collaborates with NVIDIA and partners with over 50 medical institutions. Co-founded by CEO Munjal Shah and experts from El Camino Health, Johns Hopkins, Stanford, Google, and NVIDIA. The $17 million extension to the Series A round on September 19, 2024, came from NVentures (NVIDIA’s venture arm), Greycroft, and 7Wire Ventures (Leo Shapiro), bringing total Series A funding to $137 million after the initial $53 million first close, co-led by Premji Invest and General Catalyst with participation from SV Angel, Memorial Hermann Health System, Andreessen Horowitz, and health systems like Cincinnati Children’s, WellSpan, and UHS. This occurred at a $500 million valuation. Funds support building generative AI healthcare agents with real-time, low-latency capabilities. Hippocratic AI released its first commercial product, a generative AI-based task-specific healthcare agent, three months prior to the extension.
Mar 2024Series AGeneral Catalyst (lead); Premji Invest (lead); SV Angel; Memorial Hermann Foundation; Cincinnati Children’s; Andreessen Horowitz; Universal Health Services; WellSpan Health$53M$500MHippocratic AI, founded in 2023 and headquartered in Palo Alto, develops safety-focused generative AI agents for non-diagnostic, patient-facing healthcare applications, emphasizing rigorous safety controls to address healthcare staffing shortages and improve access, equity, and outcomes. The company prioritizes safety over short-term revenue, training its foundational model, achieving key safety thresholds, and identifying novel use cases within a year of founding. On March 18, 2024, Hippocratic AI raised $53 million in an oversubscribed Series A round at a $500 million valuation, co-led by General Catalyst and Premji Invest, with participation from SV Angel, Memorial Hermann Health System, and existing investors including Andreessen Horowitz (a16z) Bio + Health, Cincinnati Children’s, WellSpan Health, and Universal Health Services. The funding supports safety testing for its staffing marketplace for healthcare and rapid growth, including partnerships with 40 health systems, payors, and digital health companies. Subsequent rounds included expansions and later series: seed funding of $65 million, Series A expanded to $70 million, Series B of $141 million in January 2025 at $1.64 billion valuation (later doubled), and Series C of $126 million (completed in parts including a $235 million tranche) at $3.5 billion valuation, bringing total funding to $404 million by late 2025. Hippocratic AI's platform spans over 1,000 clinical use cases, has handled 115 million patient interactions without safety issues across 50+ partners in six countries, and plans global expansion, product development, and selective M&A using later funds. Investors highlight its leadership in safe, empathetic AI for proactive, affordable care, backed by strategic players like NVIDIA’s NVentures, Kleiner Perkins, CapitalG, and health systems.
Jul 2023Seed-$15M--
May 2023SeedAndreessen Horowitz (lead); General Catalyst (lead)$50M--

Who has invested in Hippocratic AI?

18 investors have backed Hippocratic AI across its funding rounds, including Andreessen Horowitz, General Catalyst, Premji Invest, WellSpan Health, Universal Health Services and Kleiner Perkins.

Lead investors include Avenir, Kleiner Perkins, NVentures, General Catalyst, Premji Invest and 1 other investor.


Hippocratic AI Investors

Investors in Hippocratic AI by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA4LeadMay 2023
Andreessen HorowitzUnited StatesSan Francisco, CA4LeadMay 2023
Premji InvestIndiaBangalore3LeadMar 2024
Universal Health ServicesUnited StatesUnited States3ParticipantMar 2024
WellSpan HealthUnited StatesYork, PA3ParticipantMar 2024
SV AngelUnited StatesSan Francisco, CA2ParticipantMar 2024
Kleiner PerkinsUnited StatesSan Francisco, CA2LeadJan 2025
Cincinnati Children’sUnited StatesCincinnati, OH2ParticipantMar 2024
NVIDIAUnited StatesSan Jose, CA1ParticipantJan 2025
NVenturesUnited StatesSan Jose, CA1LeadSep 2024
John DoerrUnited StatesSan Francisco, CA1ParticipantNov 2025
Memorial Hermann FoundationUnited StatesHouston, TX1ParticipantMar 2024
7wire VenturesUnited StatesUnited States1ParticipantSep 2024

This data is available for Pro users. Sign up to see all 18 Hippocratic AI investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Hippocratic AI

Hippocratic AI has acquired 1 company to date.

Last acquisition by Hippocratic AI was on January 12th 2026. Hippocratic AI acquired Grove AI for undisclosed valuation.


Latest Acquisitions by Hippocratic AI

Grove AI
Description
Grove AI is an AI-accelerated participant relationship management system for clinical research trials. The platform automates recruitment, retention, and data collection. Boston-headquartered, it integrates with EHR systems for pharma companies.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date12 Jan 2026
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Hippocratic AI acquisitions and their M&A valuation multiples.

Start Free Trial

Hippocratic AI Competitors

Hippocratic AI competitors include listed companies like Sphere, Glaukos and U.S. Physical Therapy, and private ones like Sword Health, Abridge and EliseAI.

Public and private companies comparable to Hippocratic AI
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SphereSouth KoreaSouth KoreaPublicly listed$70M$6M$813M6.9x
Sword HealthUnited StatesNew York City, NYPrivate$240M-$4B16.7x
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x
EliseAIUnited StatesNew York City, NYPrivate$100M-$2.2B22.0x
GlaukosUnited StatesUnited StatesPublicly listed$507M($157M)$9.5B14.6x
U.S. Physical TherapyUnited StatesUnited StatesPublicly listed$781M$110M$1.2B2.3x

Hippocratic AI Public Comps

Hippocratic AI is still privately-owned, but its public comps include CCC Intelligent Solutions, Privia Health, Tieto, Affle 3i, Ncino, Doximity, Schrödinger, Haizhi, Compass Pathways and Waystar.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
CCC Intelligent Solutions$1.1B$238M4.8x4.5x21.5x10.8x
Privia Health$2.1B$44M1.0x0.9x50.2x15.3x
Tieto$2.1B$186M1.3x1.4x15.2x7.9x
Affle 3i$282M$67M7.4x6.7x31.3x29.5x
Ncino$595M$65M4.3x4.0x39.0x15.8x
Doximity$645M$229M6.3x6.2x17.7x11.9x
Schrödinger$256M($96M)7.6x7.9x(20.3x)(14.0x)
Haizhi$93M($30M)21.5x16.3x(67.1x)(440.4x)

This data is available for Pro users. Sign up to see all Hippocratic AI competitors and their valuation data.

Start Free Trial

Common questions about Hippocratic AI

When was Hippocratic AI founded?Hippocratic AI was founded in 2023.
Where is Hippocratic AI headquartered?Hippocratic AI is headquartered in San Francisco, CA, United States.
Is Hippocratic AI publicly listed?No, Hippocratic AI is a private, VC-backed company.
What is Hippocratic AI's valuation?Hippocratic AI was last valued at $3.5B in its Series C in November 2025.
How much funding has Hippocratic AI raised?Hippocratic AI has raised $402M across 6 funding rounds.
What was Hippocratic AI's last funding round?Hippocratic AI's last funding round was a $126M Series C in November 2025, led by Avenir.
Who are Hippocratic AI's investors?Hippocratic AI's investors include General Catalyst, Andreessen Horowitz, Premji Invest, Universal Health Services, WellSpan Health, SV Angel, Kleiner Perkins, Cincinnati Children’s, NVIDIA, NVentures and 8 others.
Which companies are comparable to Hippocratic AI?Companies comparable to Hippocratic AI include Sphere, Sword Health, Abridge, EliseAI, Glaukos and U.S. Physical Therapy.
How many companies has Hippocratic AI acquired?Hippocratic AI has acquired 1 company, including Grove AI.

See companies similar to Hippocratic AI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial